FENC vs. IOVA, REPL, VECT, IMTX, VALN, RLAY, OPT, DNA, TSHA, and CGEM
Should you be buying Fennec Pharmaceuticals stock or one of its competitors? The main competitors of Fennec Pharmaceuticals include Iovance Biotherapeutics (IOVA), Replimune Group (REPL), VectivBio (VECT), Immatics (IMTX), Valneva (VALN), Relay Therapeutics (RLAY), Opthea (OPT), Ginkgo Bioworks (DNA), Taysha Gene Therapies (TSHA), and Cullinan Therapeutics (CGEM). These companies are all part of the "biological products, except diagnostic" industry.
Fennec Pharmaceuticals vs.
Fennec Pharmaceuticals (NASDAQ:FENC) and Iovance Biotherapeutics (NASDAQ:IOVA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, community ranking, valuation and media sentiment.
55.5% of Fennec Pharmaceuticals shares are owned by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are owned by institutional investors. 11.8% of Fennec Pharmaceuticals shares are owned by insiders. Comparatively, 12.1% of Iovance Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Iovance Biotherapeutics received 373 more outperform votes than Fennec Pharmaceuticals when rated by MarketBeat users. Likewise, 74.16% of users gave Iovance Biotherapeutics an outperform vote while only 66.89% of users gave Fennec Pharmaceuticals an outperform vote.
Fennec Pharmaceuticals has higher earnings, but lower revenue than Iovance Biotherapeutics. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Fennec Pharmaceuticals has a beta of 0.32, meaning that its stock price is 68% less volatile than the S&P 500. Comparatively, Iovance Biotherapeutics has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500.
Fennec Pharmaceuticals has a net margin of -2.30% compared to Iovance Biotherapeutics' net margin of -451.25%. Fennec Pharmaceuticals' return on equity of -53.38% beat Iovance Biotherapeutics' return on equity.
In the previous week, Iovance Biotherapeutics had 38 more articles in the media than Fennec Pharmaceuticals. MarketBeat recorded 55 mentions for Iovance Biotherapeutics and 17 mentions for Fennec Pharmaceuticals. Fennec Pharmaceuticals' average media sentiment score of 1.05 beat Iovance Biotherapeutics' score of 0.08 indicating that Fennec Pharmaceuticals is being referred to more favorably in the media.
Fennec Pharmaceuticals presently has a consensus price target of $13.00, suggesting a potential upside of 60.89%. Iovance Biotherapeutics has a consensus price target of $13.30, suggesting a potential upside of 671.01%. Given Iovance Biotherapeutics' higher possible upside, analysts clearly believe Iovance Biotherapeutics is more favorable than Fennec Pharmaceuticals.
Summary
Iovance Biotherapeutics beats Fennec Pharmaceuticals on 10 of the 19 factors compared between the two stocks.
Get Fennec Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for FENC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fennec Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:FENC) was last updated on 5/21/2025 by MarketBeat.com Staff
Buy FENC Stock Free FENC Stock Alerts